Mobile website
Clinical Research
Clinical efficacy and prognosis of different infusion modes of DC-CIK for the treatment of primary liver cancer
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To explore the therapeutic effects and prognostic value of dendritic cell and cytokine-induced killer cell (DC-CIK) infusion in different routes in the treatment of intermediate and advanced primary liver cancer (PLC). Methods: A retrospective study was conducted on the clinical data of 69 patients with intermediate and advanced PLC treated with DC-CIK at the Oncology Department of the General Hospital of the Eastern Theater of Operations between October 2018 and September 2021. The patients were divided into a hepatic arterial infusion (HAI) group (n = 29) and an intravenous infusion (IV) group (n = 40) according to the different infusion modes used for DC-CIK treatment. The changes in peripheral blood T lymphocyte subsets (CD3+ , CD4+ , CD8+ T cells and CD4+ /CD8+ T cell ratio), cytokines (IL-2, IL-6, IFN-γ, and TNF-α), and alpha-fetoprotein (AFP) before and after treatment, treatment efficacy, overall survival (OS), and the incidence of adverse reactions were compared between the two groups. Results: After DC-CIK treatment, the objective remission rate (ORR) was 0%, and the disease control rate (DCR) was 75.8% in the HAI group; the ORR was 0%, and the DCR was 72.5% in the IV group (all P > 0.05). There were no significant changes in T-lymphocyte subpopulation between the two groups before and after treatment (all P > 0.05). The mean levels of peripheral blood IL-2, IL-6, IFN- γ and TNF- α after treatment were significantly higher than those before treatment in both groups (all P < 0.01), but with no significant difference between the two groups (all P > 0.05). The mean OS in HAI group was 48.17 months, and the OS in IV group was 39.65 months, with no significant difference between the two groups (P > 0.05). No severe adverse reactions occurred during the treatment. Conclusion: Autologous DC-CIK treatment via HAI is safe and effective for PLC. Compared to IV treatment, it tends to further improve the clinical benefit, which is worthy of clinical reference.
Keywords:
Project Supported:
Clc Number:
